Medtronic PLC 8-K filings

Medtronic plc announced its fourth quarter and full year fiscal 2026 results, showcasing 8.4% reported revenue growth for the full year and delivering the highest annual revenue growth in a decade.

Medtronic revised its fiscal year 2026 non-GAAP EPS guidance downwards following early FDA clearance of MiniMed Flex and related financial impacts.

Medtronic plc reported robust third quarter fiscal 2026 results, surpassing revenue and non-GAAP EPS guidance, driven by strong cardiovascular performance and strategic product clearances.

Medtronic plc reported strong second quarter fiscal year 2026 financial results, exceeding revenue and EPS expectations and raising its full-year guidance.

Medtronic plc announced the retirement of Gregory L. Smith, Executive Vice President of Enterprise Operations, effective December 2, 2025.

Medtronic plc shareholders overwhelmingly approved amendments to the company's Articles of Association and re-elected all directors at its 2025 Annual General Meeting.

Medtronic, Inc., a subsidiary of Medtronic plc, successfully issued €1.5 billion in new senior notes to refinance existing debt, extending maturities to 2030 and 2045.

Medtronic Inc. priced a new $1.5 billion senior notes offering to refinance existing debt, impacting fiscal year 2026 earnings per share guidance.

Medtronic plc announced robust first quarter fiscal year 2026 financial results, including mid-single digit organic revenue growth and a raised full-year EPS outlook, alongside strategic board appointments.

Medtronic plc announced the expansion of its Board of Directors and the appointment of Dr. Joon Lee, CEO of Emory Healthcare, bringing extensive clinical, academic, and executive healthcare leadership to the company.

Medtronic reports a strong finish to its fiscal year with increased revenue, EPS, and announces the intent to separate its Diabetes business into a new standalone public company.

Jennifer M. Kirk, Medtronic's Global Controller and Principal Accounting Officer, resigns to become CEO of Exubrion Therapeutics, with Denise L. Blomquist appointed as her successor.

Medtronic announces a 2.5% increase in reported revenue and a 4.1% organic revenue growth for Q3 FY25, driven by strong performance in pulsed field ablation, pacing, structural heart, diabetes, and neuromodulation.

Medtronic has announced the appointment of Thierry Pieton as its new Chief Financial Officer, effective March 3, 2025, replacing interim CFO Gary Corona.

Medtronic reported strong second-quarter fiscal year 2025 results, exceeding expectations and raising its full-year revenue and earnings per share guidance.

Medtronic's 2024 Annual General Meeting saw shareholders elect ten directors, ratify the appointment of PricewaterhouseCoopers as independent auditor, and approve several other key proposals.

Medtronic reported strong first quarter fiscal year 2025 results, driven by product innovation and diversified growth, leading to an increase in full-year guidance.

Medtronic has updated its previous 8-K filing to include details of the compensation package for its interim Chief Financial Officer, Gary Corona.

Medtronic's Chief Financial Officer, Karen Parkhill, has resigned to join HP Inc., with Gary Corona appointed as interim CFO effective August 2, 2024.

Medtronic's Executive Vice President and President, Global Regions, Rob ten Hoedt, has announced his retirement, effective June 28, 2024.

Medtronic, Inc. has successfully issued $3 billion in senior notes across four tranches to support general corporate purposes, including debt repayment.

Medtronic reports full year and fourth quarter fiscal 2024 financial results, highlighting broad-based growth and a dividend increase.

Medtronic announced strong third-quarter fiscal year 2024 results, driven by growth in key segments and international markets, leading to an increase in full-year guidance.